Categories Earnings, Health Care
Abbott Laboratories: Solid product line expected to boost Q3 results
There are few pharmaceutical companies as solid as Abbott Laboratories (NYSE: ABT). Thanks to the two major acquisitions it made a couple of years ago – St. Jude Medical and Alere – the company currently has a strong and diversified product line.
The stock has doubled in the past two years, and notably, the growth has been steady and consistent throughout this period.
Abbott will announce its third-quarter financial results on Wednesday, October 16, before the opening bell and the market is quite optimistic. Wall Street expects revenues to grow at a modest 6% to $8.11 billion, riding on the strong performance of the medical devices unit. The management had last quarter stated that it expects the pharmaceutical and diagnostics units also to improve in the second half of the financial year.
Analysts expect EPS to increase by 9 cents year-over-year to $0.84, in line with the company’s projection range of $0.83 to $0.85. Abbott views GAAP EPS between $0.53 and $0.55. The company has surpassed bottom-line estimates in two of the past four quarters while coming in line during the other two occasions.
Earlier this year, the Illinois-based firm had received FDA’s approvals for MitraClip G4, its fourth-generation heart valve repair device, and Alinity-S diagnostics system, a technology to screen and protect plasma supply. The market expects a positive impact from both these approvals in the current quarter results.
READ: Two zero-revenue biotech stocks debut in a shaky IPO market
Abbott’s ability to expand net income margins in line with the revenue increase, as well as the payout of earnings in the form of dividends make it even more attractive.
In Q2
Abbott’s second-quarter earnings topped estimates, while revenue came in line with the expectations. The company had also lifted its earnings guidance for the full-year 2019, expecting to see some acceleration in the second half.
Abbott had projected full-year 2019 GAAP earnings to be between $2.06 to $2.12 per share. Adjusted EPS from continuing operations is predicted in the range of $3.21 to $3.27.
Most Popular
AAPL Earnings: Apple’s Q2 sales and profit beat estimates; iPhone sales down 10%
Apple Inc. (NASDAQ: AAPL) on Thursday reported better-than-expected profit and revenue for the second quarter of 2024. There was a 10% decrease in iPhone sales. The gadget giant reported revenues
Shopify (SHOP) is all set to report Q1 2024 results. Here’s what to expect
Over the years, Shopify Inc. (NYSE: SHOP) has steadily expanded its footprint in the online retail market through constant innovation, like the recent launch of a mobile POS device for
eBay (EBAY): A look at how the ecommerce company fared in Q1 2024
Shares of eBay Inc. (NASDAQ: EBAY) were down over 2% on Thursday. The company reported its earnings results for the first quarter of 2024 a day ago, with revenue and